Oral Session 1-12D CLL

[OS1-12D-5] A phase II Japanese trial for rituximab in previously untreated chronic lymphocytic leukemia (CLL)

Suguru Fukuhara¹, Koji Izutsu^1,2, Tomohiro Kinoshita^3,4, Jun Takizawa⁵, Yasuo Ohashi⁶, Junji Suzumiya⁷, Kensei Tobinai¹ (1.Department of Hematology, National Cancer Center Hospital, Tokyo, Japan, 2.Department of Hematology, Toranomon Hospital, Tokyo, Japan, 3.Dept. Hematology/Cell Therapy, Aichi Cancer Center, Nagoya, Japan, 4.Japanese Red Cross Aichi Blood Center, Seto, Japan, 5.Dept. Hematology/Endocrinology/Metabolism, Niigata University Faculty of Medicine, Niigata, Japan, 6.Faculty of Science and Engineering, Chuo University, Tokyo, Japan, 7.Innovative Cancer Center/Oncology-Hematology, Shimane University Hospital, Izumo, Japan)